Skip to main content Back to Top
Advertisement

8/14/2022

Phenobarbital Injection

Products Affected - Description

    • Phenobarbital sodium intravenous injection, Hikma, 130 mg/mL, 1 mL vial, 25 count, NDC 00641-0477-25
    • Phenobarbital sodium intravenous injection, Hikma, 65 mg/mL, 1 mL vial, 25 count, NDC 00641-0476-25

Reason for the Shortage

    • Hikma did not provide a reason for the shortage.
    • BPI launched phenobarbital injection (alcohol-free) in May 2022.

Available Products

    • Phenobarbital sodium intravenous injection, BPI Labs, 130 mg/mL, 1 mL vial, 10 count, NDC 54288-0137-10
    • Phenobarbital sodium intravenous injection, BPI Labs, 65 mg/mL, 1 mL vial, 10 count, NDC 54288-0136-10

Estimated Resupply Dates

    • Hikma has phenobarbital 65 mg/mL 1 mL vials and 130 mg/mL 1 mL vials on allocation.

Updated

Updated August 14, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 8, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.